US › Healthcare

ProMIS Neurosciences Inc. (PMN)

US · Healthcare · Biotechnology

$13.57-4.03%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-8.2M
Profit YoY
-12.2%
EPS
$-1.26
EPS estimate
$-0.20

EPS came in at -1.26 against a street estimate of -0.20 — a miss of 516.1%.

Key statistics

Market cap
$123.0M
Forward P/E
0.0
P/B
2.02
Book value
$6.77
EPS (TTM)
$-18.60
52-week high
$27.40
52-week low
$6.27
50-day MA
$11.90
200-day MA
$11.98
Beta
-0.21

Analyst view

Analysts rate ProMIS Neurosciences Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $39.45.

Shareholding

Insiders
11.85%
Institutions
74.37%

Largest institutional holders

FundStake
HHG PLC14.42%
Deep Track Capital, LP9.32%
Wellington Management Company LLP7.77%
Trails Edge Capital Partners, LP6.21%
Ally Bridge Group (NY) LLC4.62%
Woodline Partners LP4.41%
Great Point Partners LLC4.14%
Yu Fan3.68%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ProMIS Neurosciences Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.